T. Sakai

发表

Synthesis and evaluation of [2-(4-quinolyloxy)phenyl]methanone derivatives: novel selective inhibitors of transforming growth factor-beta kinase.

Toshiyuki Shimizu, T. Miyazaki, K. Kimura, 2008, Journal of medicinal chemistry.

The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition.

G. Besra, M. Kronenberg, S. Porcelli, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Binding and Antigen Presentation of Ceramide-Containing Glycolipids by Soluble Mouse and Human Cd1d Molecules

M. Kronenberg, O. Naidenko, R. Modlin, 1999, The Journal of experimental medicine.

Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells.

M. Kronenberg, N. Burdin, O. Naidenko, 1998, Journal of immunology.

Quantitative and Qualitative Differences in the In Vivo Response of NKT Cells to Distinct-and -Anomeric Glycolipids

L. Kaer, Michael T. Wilson, I. Serizawa, 2004 .

Quantitative and Qualitative Differences in the In Vivo Response of NKT Cells to Distinct α- and β-Anomeric Glycolipids1

Jelena S. Bezbradica, Vrajesh V. Parekh, Michael T. Wilson, 2004, The Journal of Immunology.

Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice.

S. Snapper, D. Podolsky, S. Balk, 2000, Gastroenterology.

Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors.

Toshiyuki Shimizu, K. Kimura, T. Sakai, 2004, Bioorganic & medicinal chemistry letters.

Anomeric Glycolipids β-and α Distinctthe In Vivo Response of NKT Cells to Quantitative and Qualitative Differences in

Jelena S. Bezbradica, Vrajesh V. Parekh, L. Kaer, 2004 .

Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice.

T. Natori, M. Morita, K. Akimoto, 1995, Journal of medicinal chemistry.

Synthesis of NBD-alpha-galactosylceramide and its immunologic properties.

Y. Koezuka, T. Sakai, H. Ehara, 1999, Organic letters.

Efﬁcient Antibody Production upon Suppression of O Mannosylation in the Yeast Ogataea minuta (cid:1)

Y. Jigami, Y. Chiba, K. Ichikawa, 2007 .

Ceramide derivatives for therapeutic agents

Y. Koezuka, T. Sakai, 1998 .

Structure-activity relationship and conformational analysis of monoglycosylceramides on the syngeneic mixed leukocyte reaction.

H. Iijima, T. Natori, Y. Koezuka, 1998, Bioorganic & medicinal chemistry.

Identification of potent and selective inhibitors of PDGF receptor autophosphorylation.

T. Furuta, Toshiyuki Shimizu, R. Suzuki, 2006, Journal of medicinal chemistry.

Synthetic microbial chemistry, XVI. Synthesis of patulolides A, B, and C, new macrolides isolated from Penicillium urticae

K. Mori, T. Sakai, 1988 .

Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.

Jelena S. Bezbradica, Vrajesh V. Parekh, Michael T. Wilson, 2004, Journal of immunology.

Practical Total Synthesis of (2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol, the Antitumorial and Immunostimulatory α-Galactosylcer-amide, KRN7000.

T. Natori, M. Morita, K. Akimoto, 1996, Bioscience, biotechnology, and biochemistry.

Glycolipid derivatives as therapeutic agents

Y. Koezuka, T. Sakai, 1999 .

Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules.

H. Iijima, M. Kronenberg, Y. Koezuka, 1999, Journal of medicinal chemistry.

Effects of 3alpha- and 3beta-galactosylated alpha-galactosylceramides on the immune system.

H. Iijima, M. Morita, K. Akimoto, 1999, Bioorganic & Medicinal Chemistry Letters.

Structure-antitumor activity relationship of semi-synthetic Spicamycin derivatives.

T. Tsuruo, N. Ōtake, T. Uchida, 1995, The Journal of antibiotics.

Crucial amino acid residues of mouse CD1d for glycolipid ligand presentation to Vα14 NKT cells

H. Iijima, M. Kronenberg, M. Taniguchi, 2001 .

Efficient Antibody Production upon Suppression of O Mannosylation in the Yeast Ogataea minuta

Kazuo Kobayashi, Y. Jigami, Y. Chiba, 2007, Applied and Environmental Microbiology.

Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.

D. Im, H. Nochi, Koichi Sato, 2003, Molecular pharmacology.

Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells.

H. Nagawa, H. Arai, J. Aoki, 2004, Experimental cell research.

Lysophosphatidic Acid and Autotaxin Stimulate Cell Motility of Neoplastic and Non-neoplastic Cells through LPA1*

Masahiko Watanabe, J. Chun, Y. Kishi, 2004, Journal of Biological Chemistry.

Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites.

H. Nagawa, J. Kitayama, D. Shida, 2006, The Journal of surgical research.

Effects of α- and β-galactosylated C2-ceramides on the immune system

T. Natori, Y. Koezuka, T. Sakai, 1998 .

Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen

T. Tsuruo, N. Ōtake, T. Uchida, 1996, Cancer Chemotherapy and Pharmacology.

New synthesis of the macrolide pheromones of the rusty grain beetle, Cryptolestes ferrugineus stephens

K. Mori, T. Sakai, 1986 .

Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.

T. Tsuruo, H. Yamaki, T. Uchida, 1994, Oncology research.

CD 1-Restricted NK T Cells Galactosylceramide Recognition by Cutting Edge : Structural Requirements for Matsuda , Teruyuki Sakai and Mitchell Kronenberg

M. Kronenberg, N. Burdin, O. Naidenko, 1998 .